California-based food tech company Oobli has received FDA approval for its third sweet protein, brazzein-54, derived from the oubli fruit. This follows previous approvals for brazzein-53 and monellin, making Oobli the only supplier of oubli-derived proteins cleared by the FDA for consumer use. These proteins deliver a sugar-like taste with minimal quantity needed and no glycemic impact, offering an alternative to traditional sweeteners.

Oobli's precision fermentation method allows for consistent manufacturing of proteins originally found in tropical fruits, providing a 70% reduction in sugar content without compromising flavor. Partnerships with major companies like Ingredion and Grupo Bimbo are helping Oobli scale its ingredients portfolio, with branded products like chocolates showcasing the potential of fermentation-derived sweeteners. Oobli's sweet proteins are seen as a healthier alternative to synthetic sweeteners and have the potential to meet the demands of a market increasingly focused on nutrition and consumer preferences.